-
Posted by
Two Blokes Jun 18 -
Filed in
Stock
-
3 views
Aurora Cannabis reported mixed Q4/FY2025 results, with higher-than-expected revenues offset by lower profitability due to a number of one-time expenses. Following substantial growth in recent quarters, medical cannabis sales were essentially flat on a quarter-over-quarter basis. On the conference call, management admitted to headwinds from recent regulatory changes in Poland. As a result, medical cannabis sales and profitability are expected to decline in Q1/FY2026.
